Myelofibrosis and Polycythemia Vera: Integrating Recent Advances Into Clinical Practice

Register now for this complimentary, live 1-hour CME/CE/CPE-certified meeting where you can gain expert guidance on the optimal management of myelofibrosis and polycythemia vera and interact with faculty. Afterward, an associated downloadable slideset, on-demand Webcast, and a FAQ module will be available on the CCO Web site to enhance the information presented at the live meeting.


Distinguishing PV and MF From Other Conditions

Expert Viewpoints: Managing Select Cases in PV

  • General approach to treatment
  • Aggressive vs indolent disease phenotypes
  • Higher-risk PV
  • Uncontrolled/treatment-refractory PV

Expert Viewpoints: Managing Select Cases in MF

  • General approach to treatment
  • Symptomatic, low-risk/intermediate1–risk MF
  • Intermediate 2–risk/high-risk MF

Emerging Investigational Agents and Approaches for Managing PV and MF


Date / Time
Event Details


Brady L. Stein, MD, MHS

Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Srdan Verstovsek, MD, PhD

Division of Cancer Medicine
Department of Leukemia
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

The goal of this activity is to improve participants’ competence in and performance at treating patients with polycythemia vera and myelofibrosis.

Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with myelofibrosis or polycythemia vera.

Learning Objectives

  • Utilize clinical tools and evidence to help to distinguish the PV and MF from reactive conditions
  • Recognize the clinical impact of molecular mutations on diagnosis, prognosis, and treatment choices for patients with PV and MF
  • Analyze current and emerging clinical trial data of JAK 1/2 inhibitors in PV and MF
  • Tailor therapy for patients with PV and MF, using evidence-based guidance on best practices, safety considerations, and new data across the range of treatment settings
  • Identify ongoing trials for the treatment of PV and MF to aid referral of patients for study participation


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Continuing Education

ACPE logo

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-851-L01-P

Type of Activity

Upon completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.